 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells / SZGIMI
New P1/2 trial, CAR T-Cell Therapy: Multi-CAR T Cell Therapy for Acute Myeloid Leukemia (clinicaltrials.gov) - Jul 19, 2017
P1/2, N=10, Recruiting, Sponsor: Shenzhen Geno-Immune Medical Institute